Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Omar Ishrak received a stock grant of 665 shares of common stock as compensation. The award was made as Restricted Stock Units under Amgen’s 2009 director incentive program and vested immediately, with payment in common shares on a one-to-one basis.
After this grant, Ishrak directly holds a total of 7,358.7361 Amgen common shares. Footnotes indicate the total includes 418 dividend equivalents credited to his unvested RSUs, which will also be settled in shares according to their vesting schedule.
Amgen Inc. director Charles M. Holley reported an equity award of 665 shares of common stock, received as a grant of Restricted Stock Units (RSUs) that vested immediately at no cash cost. The RSUs were granted under Amgen’s director incentive program and are settled one-for-one in common shares. Following this grant, Holley holds 12,799.0331 shares directly and an additional 1,260 shares indirectly through the Holley Family Trust. The direct holdings include 1,564 dividend equivalent (DE) units credited on unvested RSUs, which will convert into common shares as those RSUs vest.
Garland Greg C. reported acquisition or exercise transactions in this Form 4 filing.
AMGEN INC director Greg C. Garland received 665 shares of common stock through a stock award. The award was a grant of Restricted Stock Units under Amgen’s director incentive program, which vested immediately and was settled in shares on a one-to-one basis. Following this grant, Garland directly holds 13,848 shares of Amgen common stock.
Amgen Inc. director Robert Eckert received an equity award of 665 shares of common stock on May 19, 2026, reported as a grant or other acquisition at no purchase price. The award came from vested Restricted Stock Units under Amgen’s 2009 director incentive programs and vested immediately.
After this grant, Eckert directly holds 26,251 shares of Amgen common stock. This total includes 3,943 dividend equivalents (DEs) credited to his unvested RSUs under a dividend reinvestment plan, which will pay out in shares as those RSUs vest.
Druker Brian reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Brian Druker received an equity award of 665 shares of Amgen common stock as a grant under the company’s director incentive program. The award was in the form of Restricted Stock Units (RSUs) that vested immediately and are paid in common shares on a one-to-one basis.
Following this grant, Druker directly holds 8,391 shares of Amgen common stock, which include 408 dividend equivalents (DEs) credited to his unvested RSUs under a qualifying dividend reinvestment plan.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Michael V. Drake received 665 shares of common stock as a grant of Restricted Stock Units (RSUs). The RSUs were awarded under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis. Following this award, Drake directly holds about 5,774.2869 Amgen shares, including 339 dividend equivalents credited to his unvested RSUs.
Amgen Inc. director Wanda M. Austin received a stock-based compensation award. She acquired 665 shares of Amgen common stock on May 19, 2026 through a grant classified as a “grant, award, or other acquisition,” not an open-market purchase.
The shares came from Restricted Stock Units granted under Amgen’s 2009 Director Incentive Program within the company’s equity incentive plan. According to the footnote, these RSUs vested immediately and are paid in common stock on a one-to-one basis, with an option for the director to defer receipt. Following this grant, Austin directly holds 8,018 shares of Amgen common stock.
Amgen Inc. reported the results of its annual stockholder meeting held on May 19, 2026. All 12 director nominees were elected, each receiving over 390 million votes in favor with substantial margins over votes against.
Stockholders approved the advisory vote on executive compensation, with 399,315,381 votes for and 11,987,682 against, and ratified Ernst & Young LLP as independent registered public accountants for the 2026 fiscal year with 447,904,443 votes for. A stockholder proposal to require an independent board chairman did not pass, receiving 72,902,413 votes for and 338,465,655 votes against.
Amgen Inc. announced a planned chief financial officer transition. Peter H. Griffith, executive vice president and CFO since 2020, will retire from the CFO role effective August 31, 2026 and remain as an executive vice president until his departure in January 2027.
The board approved hiring Thomas Dittrich, age 62, as executive vice president effective July 1, 2026, and he will become executive vice president and CFO on September 1, 2026. His employment offer includes an annual base salary of CHF 1,070,000, eligibility for a target bonus equal to 100% of base salary, and fiscal 2026 long-term equity incentives with a target value of CHF 4,500,000.
To replace compensation forfeited at his current employer, Dittrich will receive a one-time RSU award valued at CHF 4,700,000 and a one-time Swiss cash bonus of CHF 4,000,000, plus a separate two-year retention bonus of CHF 5,800,000. His package also includes relocation benefits, an additional relocation allowance, and a severance agreement providing two times salary and target bonus if terminated by Amgen without cause within two years of his hire date.
Amgen Inc. shareholder Capital World Investors reports beneficial ownership of 29,596,119 shares of Common Stock, equal to 5.5% of the 539,067,675 shares outstanding disclosed in the filing. The filing shows 29,296,381 shares with sole voting power and 29,596,119 shares with sole dispositive power.